Numerous vaccine strategies for cancer therapy are currently being evaluated [13], and the addition of CD40 agonist antibodies enhances the activity of tumor vaccines in nearly every case studied [14–16] providing strong rationale for combination. This evidence concerns the gene CD40 and neoplasm.